Every published Top AI Stories item tagged with Pharmaceutical Manufacturing, newest first.
Anthropic published early results from drug development partnerships. At Enveda, Claude reviewed 1,061 pages of manufacturing documents, caught all 11 issues human reviewers found plus seven they missed, and cut review time by 89 percent. At Generate Biomedicines, a Claude redesign of a CAR T-cell receptor was about 70 percent shorter and let immune cells carry roughly ten times as many receptors in lab tests. Anthropic calls the work "still at an early stage." Most results are preclinical, and its own muscular dystrophy candidate could reach human trials no sooner than late 2028.
Researchers led by Nobel laureate David Baker at the University of Washington used AI design tools to build proteases, the enzymes that cut proteins, from scratch around a known catalytic core, in two papers published in Nature. Their best designs sped up the cutting of a peptide bond roughly a billion-fold while still hitting only their intended targets, and one version cut proteins linked to Alzheimer's disease and frontotemporal dementia inside cells. Therapies are a long way off, since designed proteins are hard to deliver and can trigger immune responses, but the work shows AI design can now produce enzymes aimed at a protein researchers choose.
Microsoft Research introduced Quine, a research system that pairs a model of biology with tools, literature and wet-lab results. Working with the Broad Institute, it ranked thousands of compounds by how well they might shift pancreatic cancer cells between treatment-relevant states, and its top picks produced the largest shifts in lab assays. It also predicted a third cell state that the experiments then confirmed. Microsoft says narrowing the search took one weekend. Quine is limited to research use for now, through a new fellows program, and the results come from cell lines rather than patients.
Amazon's Bio Discovery science team described three antibody-design results, two of them in peer-reviewed journals. MochiBind predicts which of two antibodies binds a target more tightly using sequence alone, and Amazon says it scored 200,000 antibody pairs in 13 seconds on an ordinary processor. A second model predicts whether a candidate can survive manufacturing while correcting for differences between labs. The third put an agent in charge of choosing where on a target to aim. Against a target linked to desmoplastic small round cell tumor, a rare and aggressive cancer with no prior antibody or structural data, the campaign produced 46 experimentally validated strong binders. These are early lab results, not drugs, but the step from target to lead candidate normally takes six to twelve months.
Anthropic opened a research preview of the Model Hardware Standard, a shared specification for letting AI agents operate laboratory and manufacturing devices without a bespoke integration for every instrument. It borrows the shape of a device driver: hardware describes itself in a standard format and exposes simple read and write commands, so a microscope, a liquid handler or a robotic arm becomes discoverable rather than custom-wired. Genentech, Carnegie Mellon, two University of Washington protein-design labs and the quantum firm QuEra are among the first users, with Amazon Web Services, Tecan and Universal Robots building support on the vendor side. Drivers enforce device-level safety limits and can require a person to approve high-risk steps.
University of Cambridge researchers began human trials of what they call the first vaccine whose central component was designed entirely by AI. The shot targets the whole Sarbeco coronavirus family — including Covid-19, SARS, and related bat viruses — in hopes of guarding against outbreaks that have not yet emerged. An early 39-person trial tested safety; a roughly 200-person study will gauge immune response. The team is already applying the same AI design approach to influenza and Ebola vaccines.
OpenAI announced its Rosalind Biodefense Program on Friday, opening GPT-Rosalind — a frontier model fine-tuned for life-sciences work — to select US government agencies, allied nations, and a vetted set of private developers. Named applications span epidemiological modeling, early detection, screening, preparedness, non-pharmaceutical interventions, and medical countermeasure development. OpenAI says it briefed the White House and federal public-health agencies on its approach, though it has not yet published red-team or misuse-prevention details for the dual-use model.
SandboxAQ integrated its Large Quantitative Models for quantum chemistry, molecular dynamics, and microkinetics directly into Claude, letting computational and research scientists at pharmaceutical and materials companies query simulation-grade physics models in natural language without their own digital infrastructure. "For the first time, we have a frontier quantitative model on a frontier large language model that someone can access in natural language," said Nadia Harhen, SandboxAQ's general manager of AI simulation. Anthropic has not yet detailed the underlying integration mechanism.